Resource Summary Report

Generated by NIF on Apr 18, 2025

Creative Biolabs Core Facility

RRID:SCR_021767
Type: Tool

Proper Citation

Creative Biolabs Core Facility (RRID:SCR_021767)

Resource Information

URL: https://www.creative-biolabs.com/

Proper Citation: Creative Biolabs Core Facility (RRID:SCR_021767)

Description: Custom service provider that has extensive experience in various antibody production and engineering fields.Services includes mouse and rat monoclonal antibody production using hybridoma technology, human, monkey, rabbit, chicken, dog, llama and camel monoclonal antibody production using various antibody library technologies (including phage display, bacterial display and yeast display).Conducting in depth antibody humanization and affinity maturation using phage display and DNA mutagenesis approaches.OEM services for bulk scale antibody manufacturing, including bacterial production of scFv, diabody, tandem scFv, miniantibody and Fab, and mammalian cell expression of minibody, chimeric IgG, and IgG, are also available at the most competitive price in industry.

Synonyms: CB-Creative Biolabs

Resource Type: access service resource, service resource, core facility

Keywords: USEDit, ABRF, antibody production

Funding:

Resource Name: Creative Biolabs Core Facility

Resource ID: SCR_021767

Alternate IDs: ABRF_1225

Alternate URLs: https://coremarketplace.org/?FacilityID=1225

Record Creation Time: 20220129T080357+0000

Record Last Update: 20250418T055607+0000

Ratings and Alerts

No rating or validation information has been found for Creative Biolabs Core Facility.

No alerts have been found for Creative Biolabs Core Facility.

Data and Source Information

Source: SciCrunch Registry

Usage and Citation Metrics

We found 1 mentions in open access literature.

Listed below are recent publications. The full list is available at NIF.

Ma J, et al. (2022) A Novel Humanized Model of NASH and Its Treatment With META4, A Potent Agonist of MET. Cellular and molecular gastroenterology and hepatology, 13(2), 565.